FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT2662DIV2 APPLICATION NO. 10/771,766 APPLICANT VRUDHULA ET AL. FILING DATE FEBRUARY 4, 2004

Group

APR 2 9 7004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

			DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN: YES	NO
TN	1	AG	EP 0 812 831 A1	17 Dec 97	EP	,			
I	V	АН	EP 0 778 277 A1	11 Jun 97	EP				,
	V	Al	WO 98/35967	20 Aug 98	PCT				
	7	AJ	WO 99/01454	14 Jan 99	PCT				
	í/	AK	WO 99/10350	04 Mar 99	PCT				
\neg	ر.	AL	WO 99/67247	29 Dec 99	PCT				
	i/	AM	WO 00/01675	13 Jan 00	PCT				
	V	AN	WO 00/01697	13 Jan 00	PCT				
	V	AO	WO 00/39127	06 Jul 00	PCT				
	v	AP	WO 00/59907	12 Oct 00	PCT				
7/	7	AQ	WO 00/59908	12 Oct 00	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.)

TNI	AR	DUNN, et al., "Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?", Brain Research Reviews, 15, 1990, pp. 71-100 _
	AS	GULYAS, et al., "Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor," Prac. Natl. Acad. Sci. USA, 92, 1995, pp. 10575-10579
M	AT	McCARTHY, et al., "Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications," Current Pharmaceutical Design, 5, 1999, pp. 289-315

EXAMINER DATE CONSIDERED 12/2/05

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

Ý

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT2662DIV2 APPLICATION NO. 10/771,766 APPLICANT VRUDHULA ET AL. FILING DATE FEBRUARY 4, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

1 PM	AA	HOLSBOER, "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety," Journal of Psychiatric Research, 33, 1999, pp. 181-214
·	АВ	BANKI, et al., "CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse," European Neuropsychopharmacology, 2, 1992, pp. 107-113
	AC	ZOBEL, et al., "Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression, the first 20 patients treated," Journal of Psychiatric Research, 34, 2000, pp. 171-181
	AD	WEBSTER, et al., "Corticotropin-Releasing Hormone and Inflammation," Annals New York Academy of Sciences, 840, 1998, pp. 21-62
ı	AE	GILLIGAN, et al., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents," Journal of Medicinal Chemistry, 43, 9, 2000, pp. 1641-1660 1,
TWT	AF	McCARTHY, et al., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents," Annual Reports in Medicinal Chemistry, 34, 1999, pp. 11-20
	AG	
	АН	
	Al	
	AJ	
	AK	
	ĄĻ	
	АМ	
,	AN	
EXAMINE	R	DATE CONSIDERED ,_/_/

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a fine through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 3 of 3

FORM PTO-1449 (REV. 7-85)

4

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT2662DIV2 APPLICATION NO. 10/771,766 APPLICANT VRUDHULA ET AL. FILING DATE FEBRUARY 4, 2004

Group

FOREIGN PATENT DOCUMENTS

,		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION YES NO	
TWO	AA	EP 0 902 029 A1	17 Mar 99	EPO				
/ / Y \ 	AB	WO 01/007440 A	01 Feb 01	PCT				
1	AC	EP 0 970 958 A	12 Jan 00	EPO				
TNI	ÁD	WO 97/29109 A	14 Aug 97	PCT				
1	AE							
	AF							
	AG							
	AH							
	Al							
	AJ							
	AK			·				
	AL							
	АМ							
	AN							
	AO							
	AP							
	AQ							
	AR							
	AS							
	AT							
	AU							
	AV							
	AW							
	AX							
	AY							
	AZ							
EXAMINE	R	Tels	m	DATE CONSIDERED	(2/	2/03		

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.